posted on 2022-12-21, 12:18authored byOndrej Belan, Marie Sebald, Marek Adamowicz, Roopesh Anand, Aleksandra Vancevska, Joana Neves, Vera Grinkevich, Graeme Hewitt, Sandra Segura-Bayona, Roberto Bellelli, Helen MR Robinson, Geoff S Higgins, Graeme CM Smith, Stephen C West, David S Rueda, Simon J Boulton
POLQ is a key effector of DSB repair by microhomology-mediated end-joining (MMEJ) and is overexpressed in many cancers. POLQ inhibitors confer synthetic lethality in HR and Shieldin-deficient cancer cells, which has been proposed to reflect a critical dependence on the DSB repair pathway by MMEJ. Whether POLQ also operates independent of MMEJ remains unexplored. Here, we show that POLQ-deficient cells accumulate post-replicative ssDNA gaps upon BRCA1/2 loss or PARP inhibitor treatment. Biochemically, cooperation between POLQ helicase and polymerase activities promotes RPA displacement and ssDNA-gap fill-in, respectively. POLQ is also capable of microhomology-mediated gap skipping (MMGS), which generates deletions during gap repair that resemble the genomic scars prevalent in POLQ overexpressing cancers. Our findings implicate POLQ in mutagenic post-replicative gap sealing, which could drive genome evolution in cancer and whose loss places a critical dependency on HR for gap protection and repair and cellular viability.
Funding
Crick (Grant ID: CC2098, Grant title: West CC2098)
Crick (Grant ID: CC2057, Grant title: Boulton CC2057)
European Research Council (Grant ID: 742437 - TelMetab, Grant title: ERC 742437 - TelMetab)